After discovering that lack of Sost/sclerostin expression is the cause of the high bone mass
human syndromes Van Buchem disease and sclerosteosis, extensive animal …

Controlling the excessive fracture burden in patients with chronic kidney disease (CKD)
Stages G4–G5D remains an impressive challenge. The reasons are 2-fold. First, the …

Background Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin,
increases bone formation, and decreases bone resorption. Methods We enrolled 4093 …

Wnt signaling and its bone tissue–specific inhibitor sclerostin are key regulators of bone
homeostasis. The therapeutic potential of anti-sclerostin antibodies (Scl-Abs), for bone mass …

The processes of bone growth, modeling, and remodeling determine the structure, mass,
and biomechanical properties of the skeleton. Dysregulated bone resorption or bone …

Alkaline phosphatase (ALP) is an evolutionary conserved enzyme and widely used
biomarker in clinical practice. Tissue-nonspecific alkaline phosphatase (TNALP) is one of …

In addition to its structural role, the skeleton serves as an endocrine organ that controls
mineral metabolism and energy homeostasis. Three major cell types in bone-osteoblasts …

As the GFR loss aggravates, the disturbed mineral metabolism worsens the bone
microstructure and remodelling‐scenario, which is known as CKD‐mineral bone disease …

The chronic kidney disease–mineral and bone disorder (CKD–MBD) syndrome is an
extremely important complication of kidney diseases. Here we tested whether CKD–MBD …

In the course of chronic kidney disease (CKD), alterations in the bone-vascular axis
augment the risk of bone loss, fractures, vascular and soft tissue calcification, left ventricular …